Decreasing Unnecessary Pharmacy Cost in the Cath Lab

Abstract

AngioMax is a single dose heparin alternative introduced in 2002 that is used in cardiac patients undergoing percutaneous intervention (PCI). Bivalirudin costs $377 per dose; heparin is less than$15 per dose. Noting practice variations, the Cath Lab set out to eliminate unnecessary pharmacy cost for PCI patients by: Using current literature to inform clinical care Standardizing practice Using data to track and guide implementationhttps://digitalcommons.centracare.com/nursing_posters/1097/thumbnail.jp